Dr. Shaw's major research interests include studying anaplastic lymphoma kinase (ALK) and ROS1 rearrangements in non-small cell lung carcinoma (NSCLC). She is also studying how lung cancers develop resistance to targeted therapies, and this work has led to a number of novel treatment strategies to overcome resistance in the clinic. Dr Shaw has been awarded a number of research grants, including grants from the Damon Runyon Cancer Research Foundation, the Burroughs Welcome Fund, the V Foundation for Cancer Research, Uniting Against Lung Cancer, the National Foundation for Cancer Research, and the NIH/NCI.